11.02.2020 | Tracker

FDA Tracker: Novo Nordisk’s Ozempic and Rybelsus the most mentioned approvals

By Nathan Cripps

FDA Tracker: Novo Nordisk’s Ozempic and Rybelsus the most mentioned approvals

CREATION Pinpoint’s Drug Launch Tracker shows how healthcare professionals (HCPs) respond to drug launch news, as it happens. The FDA approved over 390 submissions between 11 January 2020 – 10 February 2020, which included medications that reduce the risk of cardiovascular disease, block the effects of opioids and improve glycemic control in type 2 diabetes patients.

The most mentioned FDA approvals by HCPs online

OzempicsemaglutideNovo Nordisk264571
RybelsussemaglutideNovo Nordisk242448
Tepezzateprotumumab-trbwHorizon Therapeutics Ireland14923
Trijardy XrempagliflozinBoehringer Ingelheim15318
DificidfidaxomicinCubist Pharms Llc358
ColchicinecolchicineGranules Pharms336
JardianceempagliflozinBoehringer Ingelheim404
SublocadebuprenorphineIndivior Inc123
Tazveriktazemetostat hydrobromideEpizyme Inc303
Ajovyfremanezumab-vfrmTeva Pharms Usa202
Monoferricferric derisomaltosePharmacosmos As022
PemfexypemetrexedEagle Pharms112
SabrilvigabatrinLundbeck Pharms Llc112
Sildenafil Citratesildenafil citrateAmneal Pharms112
TestosteronetestosteroneLupin Ltd112
EpipenepinephrineMylan Speciality Lp101

This month Novo Nordisk’s Ozempic and Rybelsus (semaglutide) were the top two products mentioned regarding their FDA approval. HCPs shared the news that Ozempic has been approved in a new indication and Rybelsus has been given additional prescribing details. These have both been approved for the risk reduction of major adverse cardiovascular events, such as heart attack and stroke, in patients with type 2 diabetes (T2D). Christopher Cannon, a cardiologist in Boston, shared that the approval of Ozempic is a huge advance for T2D management which was then shared by four HCPs.

Horizon Therapeutics’ Tepezza (teprotumumab), the first and only FDA approved medicine for thyroid eye disease, was the third most mentioned product this month with 23 HCP mentions.

We are tracking the HCP reaction to FDA approvals and related topics each month. You can keep up to date with this and other pharmaceutical tracking updates within the Tracking section of CREATION Knowledge, or by signing up to our monthly eJournal.


FDA Tracker: HCPs excited for Keytruda® approval but share reservations about Vascepa®

Methodology notes:

  • Data for this research was analysed from the online Twitter conversations of HCPs talking about FDA approvals in English language (all other languages are available), between January 11th 2020 and February 10th 2020.
  • Between January 11th 2020 and February 10th 2020, 878 HCPs shared posts about FDA approvals 1,572 times all over the world.
  • The table refers only to approvals that occurred between January 11th 2020 and February 10th 2020. Mentions of approvals before January 11th were not included.
  • HCPs mention brand and compound names when discussing FDA approvals. Approvals may include multiple brands and compounds.

View all articles >

Meet the Author

Nathan Cripps

Suggested next

#WhatHCPsThink About Virtual Congress

18.06.2020 | Article

#WhatHCPsThink About Virtual Congress

#WhatHCPsThink About Virtual Congress

By Lara Meyer

Conversation network of HCPs discussing type 2 diabetes online

29.09.2023 | Article

Understanding conversation networks within online HCP communities

There is a significant cluster of highly conversation-connected cardiology specialists

By Francesca Gan

View all articles >